Prevention of typhoid fever

Advances in Experimental Medicine and Biology

Volumn 568, Issue , 2005, Pages 161-173

  Levine, Myron M ^a   Lepage, Philippe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARRIER PROTEIN; CIPROFLOXACIN; LIVE VACCINE; NORFLOXACIN; PSEUDOMONAS EXOTOXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TYPHOID VACCINE; TYPHOID PARATYPHOID VACCINE;

ABSENTEEISM; ANTIBODY BLOOD LEVEL; CLINICAL TRIAL; DISEASE CARRIER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDEMIC DISEASE; ENVIRONMENTAL IMPACT ASSESSMENT; FEVER; HUMAN; IMMUNIZATION; INJECTION SITE REACTION; MALAISE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SALMONELLA; SECONDARY PREVENTION; SIDE EFFECT; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR; SALMONELLA TYPHI; VACCINATION;

HUMANS; RISK FACTORS; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION;

EID: 25144519107     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-25342-4_11     Document Type: Review

References (70)

1. Acharya, V.I., Lowe, C.U., Thapa, R., Gurubacharya, V.L., Shrestha, M.B., Cadoz, M. et al. (1987). Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 317, 1101-1104.
2. Azze, R.F., Rodriguez, J.C., Iniesta, M.G., Marchena, X.R., Alfonso, V.M., and Padron, F.T. (2003). Immunogenicity of a new Salmonella typhi Vi polysaccharide vaccine-vax-TyVi-in Cuban school children and teenagers. Vaccine 21(21-22), 2758-2760.
3. Begier, E.M., Burwen, D.R., Haber, P., and Ball, R. (2004). Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin. Infect. Dis. 38(6), 771-779.
4. Bhutta, Z.A. (1996). Therapeutic aspects of typhoidal salmonellosis in childhood: The Karachi experience. Ann. Trop. Paediatr. 16, 299-306.
5. Black, R.E., Levine, M.M., Ferreccio, C., Clements, M.L., Lanata, C., Rooney, J. et al. (1990). Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 8, 81-84.
6. Butler, T., Linh, N.N., Arnold, K., and Pollack, M. (1973). Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor. Lancet 2, 983-985.
7. Canh, D.G., Lin, F.Y., Thiem, V.D., Trach, D.D., Trong, N.D., Mao, N.D. et al. (2004). Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect. Immun. 72(11), 6586-6588.
8. Cao, X.T., Kneen, R., Nguyen, T.A., Truong, D.L., White, N.J., and Parry, C.M. (1999). A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr. Infect. Dis. J. 18(3), 245-248.
9. Cote, T.R., Convery, H., Robinson, D., Ries, A., Barrett, T., Frank, L. et al. (1995). Typhoid fever in the park: Epidemiology of an outbreak at a cultural interface. J. Community Health 20(6), 451-458.
10. R). Lancet 341, 49-50.
11. Cryz, S.J., Jr., Vanprapar, N., Thisyakorn, U., Olanratmanee, T., Losonsky, G., Levine, M.M. et al. (1993). Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect. Immun. 61, 1149-1151.
12. Ferreccio, C., Levine, M.M., Manterola, A., Rodriguez, G., Rivara, I., Prenzel, I. et al. (1984). Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J. Pediatr. 104, 899-901.
13. Ferreccio, C., Levine, M.M., Rodriguez, H., and Contreras, R. (1989). Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area. J. Infect. Dis. 159, 766-769.
14. Ferreccio, C., Levine, M.M., Solari, V., Misraji, A., Astroza, L., Berrios, G. et al. (1990). Detección de portadores cronicos de S. typhi: Metodo practice aplicado a manipuladores de alimentos del centro de Santiago. Rev. Med. Chil. 118, 33-37.
15. Ferreccio, C., Morris, J.G., Valdivieso, C., Prenzel, I., Sotomayor, V., Drusano, G.L. et al. (1988). Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J. Infect. Dis. 157, 1235-1239.
16. Germanier, R. and Furer, E. (1975). Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: A candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141, 553-558.
17. Gilman, R.H., Islam, S., Rabbani, H., and Ghosh, H. (1979). Identification of gallbladder typhoid carriers by a string device. Lancet 1(8120), 795-796.
18. Gilman, R.H., Terminel, M., Levine, M.M., Hernandez Mendosa, P., Calderone, E., Vasquez, V. et al. (1975). Comparison of trimethoprim- sulfamethoxazole and amoxicillin in therapy of chloramphenicol-resistant and chloramphenicol-sensitive typhoid fever. J. Infect. Dis. 132, 630-636.
19. Gotuzzo, E., Guerra, J.G., Benavente, L., Palomino, J.C., Carrillo, C., Lopera, J. et al. (1988). Use of norfloxacin to treat chronic typhoid carriers. J. Infect. Dis. 157(6), 1221-1225.
20. Gupta, A. (1994). Multidrug-resistant typhoid fever in children: Epidemiology and therapeutic approach. Pediatr. Infect. Dis. J. 13, 124-140.
21. Hindle, Z., Chatfield, S.N., Phillimore, J., Bentley, M., Johnson, J., Cosgrove, C.A. et al. (2002). Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 70(7), 3457-3467.
22. Hohmann, E.L., Oletta, C.A., Killeen, K.P., and Miller, S.I. (1996). phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173, 1408-1414.
23. Hornick, R.B., Greisman, S.E., Woodward, T.E., DuPont, H.L., Dawkins, A.T., and Snyder, M.J. (1970). Typhoid fever; pathogenesis and immunologic control. N. Engl. J. Med. 283, 686-691, 739-746.
24. Ivanoff, B., Levine, M.M., and Lambert, P.H. (1994). Vaccination against typhoid fever: Present status. Bull. World Health Organ. 72(6), 957-971.
25. JAMA. (1920). Typhoid in the large cities of the United States in 1919. J. Am. Med. Assoc. 672-675.
26. Keitel, W.A., Bond, N.L., Zahradnik, J.M., Cramton, T.A., and Robbins, J.B. (1994). Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12(3), 195-199.
27. Klugman, K., Gilbertson, I.T., Kornhoff, H.J., Robbins, J.B., Schneerson, R., Schulz, D. et al. (1987). Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet 2, 1165-1169.
28. Klugman, K.P., Koornhof, H.J., Robbins, J.B., and Le Cam, N.N. (1996). Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14(5), 435-438.
29. Kossaczka, Z., Lin, F.Y., Ho, V.A., Thuy, N.T., Van Bay, P., Thanh, T.C. et al. (1999). Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67(11), 5806-5810.
30. Lanata, C.F., Levine, M.M., Ristori, C., Black, R.E., Jimenez, L., Salcedo, M. et al. (1983). Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet 2, 441-443.
31. Lanata, C.F., Tafur, C., Benavente, L., Gotuzzo, E., and Carrillo, C. (1990). Detection of Salmonella typhi carriers in food handlers by Vi serology in Lima, Peru. Bull. Pan Am. Health Organ. 24(2), 177-182.
32. Lebacq, E. (2001). Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration. BioDrugs 15 (Suppl 1), 5-12.
33. Lepage, P., Bogaerts, J., Van Goethem, C., Ntahorutaba, M., Nsengumuremyi, F., Hitimana, D.G. et al. (1987). Community-acquired bacteraemia in African children. Lancet 1(8548), 1458-1461.
34. Levine, M.M. (2003). Use of vaccines for the prevention of typhoid fever. Indian Pediatr. 40(11), 1029-1034.
35. Levine, M.M., Black, R.E., Lanata, C., and Chilean Typhoid Committee. (1982). Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J. Infect. Dis. 146, 724-726.
36. Levine, M.M., Ferreccio, C., Abrego, P., Martin, O.S., Ortiz, E., and Cryz, S. (1999). Duration of efficacy of Ty21a, attenuated salmonella typhi live oral vaccine. Vaccine 17 (Suppl 2), S22-S27.
37. Levine, M.M., Ferreccio, C., Black, R.E., Germanier, R., and Chilean Typhoid Committee. (1987). Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1, 1049-1052.
38. Levine, M.M., Ferreccio, C., Black, R.E., Tacket, C.O., Germanier, R., and Chilean Typhoid Committee. (1989a). Progress in vaccines to prevent typhoid fever. Rev. Infect. Dis. 11 (Suppl 3), S552-S567.
39. Levine, M.M., Ferreccio, C., Cryz, S., and Ortiz, E. (1990). Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 336, 891-894.
40. Levine, M.M., Taylor, D.N., and Ferreccio, C. (1989b). Typhoid vaccines come of age. Pediatr. Infect. Dis. J. 8, 374-381.
41. Lin, F.Y., Becke, J.M., Groves, C., Lim, B.P., Israel, E., Becker, E.F. et al. (1988). Restaurant-associated outbreak of typhoid fever in Maryland: Identification of carrier facilitated by measurement of serum Vi antibodies. J. Clin. Microbiol. 26(6), 1194-1197.
42. Lin, F.Y.C., Ho, V.A., Khiem, H.B., Trach, D.D., Bay, P.V.T.T.C., Kossaczka, Z. et al. (2001). The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344, 1263-1268.
43. Losonsky, G.A., Ferreccio, C., Kotloff, K.L., Kaintuck, S., Robbins, J.B., and Levine, M.M. (1987). Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J. Clin. Microbiol. 25, 2266-2269.
44. Mahle, W.T. and Levine, M.M. (1993). Salmonella typhi infection in children younger than five years of age. Pediatr. Infect. Dis. J. 12, 627-631.
45. Mai, N.L., Phan, V.B., Vo, A.H., Tran, C.T., Lin, F.Y., Bryla, D.A. et al. (2003). Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349(14), 1390-1391.
46. Mermin, J.H., Townes, J.M., Gerber, M., Dolan, N., Mintz, E.D., and Tauxe, R.V. (1998). Typhoid fever in the United States, 1985-1994: Changing risks of international travel and increasing antimicrobial resistance. Arch. Intern. Med. 158(6), 633-638.
47. Mermin, J.H., Villar, R., Carpenter, J., Roberts, L., Samaridden, A., Gasanova, L. et al. (1999). A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J. Infect. Dis. 179(6), 1416-1422.
48. Mikhail, I.A., Haberberger, R.L., Farid, Z., Girgis, N.I., and Woody, J.N. (1989). Antibiotic-multiresistant Salmonella typhi in Egypt. Trans. R. Soc. Trop. Med. Hyg. 83, 120.
49. Olanratmanee, T., Levine, M.M., Losonsky, G., Thisyakorn, U., Cryz, S.J., Jr., and Cryz, S.J., Jr. (1992). Safety and immunogenicity of Salmonella typhi Ty21a liquid forumlation vaccine in 4- to 6-year-old Thai children. J. Infect. Dis. 166, 451-452.
50. Pfeiffer, R. and Kolle, W. (1896). Experimentelle Untersuchunger zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Dtsch. Med. Wocheschr. 22, 735-737.
51. Plotkin, S.A. and Bouveret-Le Cam, N. (1995). A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch. Intern. Med. 155, 2293-2299.
52. Robbins, J. and Robbins, J. (1984). Reexamination of the protective role of the capsular polysaccharide Vi antigen of Salmonella typhi. J. Infect. Dis. 150, 436-449.
53. Rowe, B., Ward, L.R., and Threlfall, E.J. (1997). Multidrug-resistant Salmonella typhi: A worldwide epidemic, Clin. Infect. Dis. 24 (Suppl 1), S106-S109.
54. Sabitha, P., Prabha Adhikari, M.R., Chowdary, A., Prabhu, M., Soofi, M., Shetty, M. et al. (2004). Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine. Indian J. Med. Sci. 58(4), 141-149.
55. Salerno-Goncalves, R., Wyant, T.L., Pasetti, M.F., Fernandez-Vina, M., Tacket, C.O., Levine, M.M. et al. (2003). Concomitant induction of CD4(+) and CD8(+) T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J. Immunol. 170(5), 2734-2741.
56. Simanjuntak, C., Paleologo, F., Punjabi, N., Darmowitogo, R., Soeprawato, Totosudirjo, H. et al. (1991). Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338, 1055-1059.
57. Sinha, A., Sazawal, S., Kumar, R., Sood, S., Reddaiah, V.P., Singh, B. et al. (1999). Typhoid fever in children aged less than 5 years. Lancet 354(9180), 734-737.
58. Steinberg, E.B., Bishop, R., Haber, P., Dempsey, A.F., Hoekstra, R.M., Nelson, J.M. et al. (2004). Typhoid fever in travelers: Who should be targeted for prevention? Clin. Infect. Dis. 39(2), 186-191.
59. Stephens, I. and Levine, M.M. (2002). Management of typhoid fever in children. Pediatr. Infect. Dis. J. 21(2), 157-158.
60. Tacket, C.O., Pasetti, M.F., Sztein, M.B., Livio, S., and Levine, M.M. (2004). Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. 190(3), 565-570.
61. Tacket, C.O., Sztein, M.B., Losonsky, G.A., Wasserman, S.S., Nataro, J.P., Edelman, R. et al. (1997). Safety of live oral Salmonella typhi vaccine strains with deletions in HtrA and aroC aroD and immune response in humans. Infect. Immun. 65, 452-456.
62. Tacket, C.O., Sztein, M.B., Wasserman, S.S., Losonsky, G., Kotloff, K.L., Wyant, T.L. et al. (2000). Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68(3), 1196-1201.
63. Wahdan, M.H., Serie, C., Cerisier, Y., Sallam, S., and Germanier, R. (1982). A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three year results. J. Infect. Dis. 145, 292-296.
64. Wahdan, M.H., Serie, Ch., Germanier R., Lackany, A., Cerisier, Y., Guerin, N., et al. (1980). A controlled field trial of live oral typhoid vaccine Ty21a. Bull. World Health Organ. 58, 469-474.
65. Wang, J.Y, Noriega, F.R., Galen, J.E., Barry, E., and Levine, M.M. (2000). Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect. Immun. 68, 4647-4652.
66. Wolman, A. and Gorman, A. (1931). The Significance of Waterborne Typhoid Fever Outbreaks. Williams & Wilkins, Baltimore.
67. Wong, K.H., Feeley, J.C., Northrup, R.S., and Forlines, M.E. (1974). Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect. Immun. 9, 348-353.
68. Woodward, T.E., Smadel, J.E., Ley, H.L., Green, R., and Mankakan, D.S. (1948). Preliminary report on the beneficial effect of choloromycetin in the treatment of typhoid fever. Ann. Intern. Med. 29, 131-134.
69. Wright, A.E. and Semple, D. (1897). Remarks on vaccination against typhoid fever. Br. Med. J. 1, 256-258.
70. Yang, H.H., Wu, C.G., Xie, G.Z., Gu, Q.W., Wang, B.R., Wang, L.Y et al. (2001). Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull. World Health Organ. 79(7), 625-631.